New report on intellectual property, 5 things you should know about Medicare Part D, and more
Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending - The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp│analytics. According to the analysis, the industry had the highest research and development (R&D) investment over the last decade, accounting for 27 percent of average annual R&D spending from 2000-2012.
A Short Video on Medicare Part D - Medicare Part D provides nearly 40 million older Americans and people living with disabilities with affordable access to prescription drug coverage. There’s a lot of information out there on the Part D program and its success. To help people better understand how the program helps save money and keep beneficiaries healthy, check out our new video that highlights the five things you should know about Part D.
PhRMA Statement on Energy & Commerce Health Subcommittee 340B Hearing - PhRMA CEO John J. Castellani sent a statement for the record to the Energy and Commerce Health Subcommittee on the hearing being held on the 340B program.
Learning and Action Network Kickoff Meeting – PhRMA has long supported policies to advance affordable, high-quality, individualized care, and we were pleased to participate in this week’s inaugural meeting of the Learning and Action Network (LAN), an initiative of HHS to discuss payment and delivery reform.
For more from PhRMA visit catalyst.phrma.org.
Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.